PARGY-LAD Facts
Psychedelic;
Description
PARGY-LAD (6-propargyl-6-nor-LSD) is a semi-synthetic psychedelic of the lysergamide class. It activates serotonin receptors in the cortex, disrupting normal sensory filtering and producing the visual and cognitive shifts characteristic of classical psychedelics.[1]
Subjective effects include geometric visual patterns, time alteration, altered conceptual thinking, ego dissolution, and mood shifts. The experience is qualitatively similar to LSD — a broad shift in perception and thought — but arrives at higher doses and resolves somewhat sooner.[2][3]
PARGY-LAD does not produce physical dependence, and rapid tolerance after a single dose makes compulsive use self-limiting.[4] The primary danger is psychological — anxiety, paranoia, and disorientation scaling with dose — compounded by the near-impossibility of verifying that any sample labeled PARGY-LAD is authentic.
Dose and durationby route · individual sensitivity varies
Starts in 30 – 45 minLasts 6 – 8 hoursAfter-effects 2 – 6 hours
Body and dependence
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Physical dependence
- None
- Psychological dependence
- Negligible
- Withdrawal
- None recorded
- Compulsive redosing
- Negligible
Tolerance
- Builds
- Rapid
- Fully resets after
- 14 days
- Carries over to
- LSD;
psilocybin; mescaline; DMT; AL-LAD; ETH-LAD
Effectslikely at a common dose
- Perception
- Music enhancement;
Visual drifting; Color alteration; Color enhancement; Geometry; Visual breathing; +31 possible, including Spatial disorientation, Vestibular distortion, Visual haze / noise - Body
- Stimulation;
Pupil dilation; Wakefulness; Body scan awareness; +32 possible, including Insomnia, Nausea, Muscle tension - Thinking
- Novelty enhancement;
Introspection enhancement; Conceptual thinking; Thought connectivity; Aesthetic enhancement; Cognitive flexibility; Openness enhancement; +24 possible, including Thought loops, Suggestibility enhancement, Memory suppression - Feeling
- Emotional enhancement;
Euphoria; +7 possible, including Emotional lability, Anxiety, Dysphoria - Self
- none likely · 10 possible, including Derealization, Depersonalization, Communication suppression
- Time
- Time alteration;
+4 possible, including Temporal disorientation - Transpersonal
- none likely · 1 possible
- Awareness
- none likely · 4 possible
Who shouldn't take it
Combinations60 recorded
Seek help immediately if
Most difficulty is psychological (intense fear, panic, confusion) and passes with calm support — the signs below mean seek emergency help:
- Very high body temperature; hot, dry skin
- Seizures
- Chest pain; fast or irregular heartbeat
- Severe muscle rigidity, tremor, or twitching (possible serotonin syndrome)
- Cold, pale, or blue fingers/toes — severe vasoconstriction (notably NBOMe / DOx)
- Persistent vomiting; unconsciousness; uncontrollable agitation or risk of self-harm
What to do
- Stay calm and reassure — remind them they took a drug and the effect will pass
- Move to a calm, quiet, safe space with low light; reduce noise and sensory input
- Keep them from harm — they may act on fear or confusion; stay with them, don't leave them alone
- Talk them down gently; don't grab or restrain unless they're in danger
- For the medical signs above (overheating, seizure, chest pain, vasoconstriction, unresponsive) call emergency services
- If overheating, cool the body; be ready to give rescue breaths / CPR
The experience is time-limited and usually resolves with calm reassurance in a safe setting — psychological first aid, not medication. Serious physical harm is uncommon for classic psychedelics (LSD, psilocybin) but real for some potent phenethylamines (NBOMe, DOx), where hyperthermia, seizures, and vasoconstriction warrant emergency care.
988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE
References
- [1]
- [2]
- [3]
- [4]^de la Fuente Revenga M, Jaster AM, McGinn J, Silva G, Saha S, Gonzalez-Maeso J (2022) Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice — ACS Chemical Neuroscience doi:10.1021/acschemneuro.2c00170